Global Sartan-series Drugs Market Growth (Status and Outlook) 2024-2030

Global Sartan-series Drugs Market Growth (Status and Outlook) 2024-2030

Sartan-series drugs are one of the commonly used clinical antihypertensive drugs, ending with "sartan", such as losartan, valsartan, telmisartan, also known as angiotensin II receptor antagonists or Angiotensin receptor blocker (ARBs). They include irbesartan, valsartan, losartan and candesartan. If the name of a medicine ends in ‘sartan’, it is an ARB.

The global Sartan-series Drugs market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LPI (LP Information)' newest research report, the “Sartan-series Drugs Industry Forecast” looks at past sales and reviews total world Sartan-series Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Sartan-series Drugs sales for 2023 through 2029. With Sartan-series Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Sartan-series Drugs industry.

This Insight Report provides a comprehensive analysis of the global Sartan-series Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Sartan-series Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Sartan-series Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Sartan-series Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Sartan-series Drugs.

United States market for Sartan-series Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Sartan-series Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Sartan-series Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Sartan-series Drugs players cover Novartis, Merck & Co, Sanofi, Pfizer, Bayer, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Sartan-series Drugs market by product type, application, key players and key regions and countries.

Segmentation by Type:
Losartan
Valsartan
Irbesartan
Telmisartan
Olmesartan
Candesartan
Sacubitril/valsartan
Others

Segmentation by Application:
Hospital Pharmaty
Retail Pharmacy

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
Losartan
Valsartan
Irbesartan
Telmisartan
Olmesartan
Candesartan
Sacubitril/valsartan
Others

Segmentation by Application:
Hospital Pharmaty
Retail Pharmacy

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
Merck & Co
Sanofi
Pfizer
Bayer
AstraZeneca
Daiichi Sankyo
Takeda
Bristol-Myers Squibb Company
Boehringer Ingelheim
Abbott
Teva Pharmaceutical
Shenzhen Salubris Pharmaceuticals

Please note: The report will take approximately 2 business days to prepare and deliver.